日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Adjuvant crizotinib in high-risk uveal melanoma following definitive therapy

克唑替尼辅助治疗用于高危葡萄膜黑色素瘤患者根治性治疗后

Khan, Shaheer; Lutzky, Jose; Shoushtari, Alexander N; Jeter, Joanne; Marr, Brian; Olencki, Thomas E; Cebulla, Colleen M; Abdel-Rahman, Mohamed; Harbour, J William; Sender, Naomi; Nesson, Alexandra; Singh-Kandah, Shahnaz; Hernandez, Susana; King, Jeanelle; Katari, Manpreet S; Dimapanat, Lyssa; Izard, Stephanie; Ambrosini, Grazia; Surriga, Oliver; Rai, Alex J; Chiuzan, Codruta; Schwartz, Gary K; Carvajal, Richard D

Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma

接受一线帕博利珠单抗治疗的晚期默克尔细胞癌患者的三年生存率、相关因素和挽救治疗

Nghiem, Paul; Bhatia, Shailender; Lipson, Evan J; Sharfman, William H; Kudchadkar, Ragini R; Brohl, Andrew S; Friedlander, Philip A; Daud, Adil; Kluger, Harriet M; Reddy, Sunil A; Boulmay, Brian C; Riker, Adam; Burgess, Melissa A; Hanks, Brent A; Olencki, Thomas; Kendra, Kari; Church, Candice; Akaike, Tomoko; Ramchurren, Nirasha; Shinohara, Michi M; Salim, Bob; Taube, Janis M; Jensen, Erin; Kalabis, Mizuho; Fling, Steven P; Homet Moreno, Blanca; Sharon, Elad; Cheever, Martin A; Topalian, Suzanne L

Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy

接受帕博利珠单抗一线治疗的晚期默克尔细胞癌患者的肿瘤持久消退和总生存期

Nghiem, Paul; Bhatia, Shailender; Lipson, Evan J; Sharfman, William H; Kudchadkar, Ragini R; Brohl, Andrew S; Friedlander, Phillip A; Daud, Adil; Kluger, Harriet M; Reddy, Sunil A; Boulmay, Brian C; Riker, Adam I; Burgess, Melissa A; Hanks, Brent A; Olencki, Thomas; Margolin, Kim; Lundgren, Lisa M; Soni, Abha; Ramchurren, Nirasha; Church, Candice; Park, Song Y; Shinohara, Michi M; Salim, Bob; Taube, Janis M; Bird, Steven R; Ibrahim, Nageatte; Fling, Steven P; Homet Moreno, Blanca; Sharon, Elad; Cheever, Martin A; Topalian, Suzanne L

A Phase I/II Trial of Cetuximab in Combination with Interleukin-12 Administered to Patients with Unresectable Primary or Recurrent Head and Neck Squamous Cell Carcinoma

一项针对无法切除的原发性或复发性头颈部鳞状细胞癌患者的西妥昔单抗联合白细胞介素-12治疗的I/II期临床试验

McMichael, Elizabeth L; Benner, Brooke; Atwal, Lakhvir S; Courtney, Nicholas B; Mo, Xiaokui; Davis, Melanie E; Campbell, Amanda R; Duggan, Megan C; Williams, Kallan; Martin, Kyle; Levine, Kala; Olaverria Salavaggione, Gonzalo N; Noel, Tiffany; Ganju, Akaansha; Uppati, Sarvani; Paul, Bonnie; Olencki, Thomas; Teknos, Theodoros N; Savvides, Panos; Tridandapani, Susheela; Byrd, John C; Caligiuri, Michael A; Liu, Stephen V; Carson, William E 3rd

A pilot study of interferon-alpha-2b dose reduction in the adjuvant therapy of high-risk melanoma

一项关于降低干扰素α-2b剂量用于高危黑色素瘤辅助治疗的初步研究

Suarez-Kelly, Lorena P; Levine, Kala M; Olencki, Thomas E; Del Campo, Sara E Martin; Streacker, Elizabeth A; Brooks, Taylor R; Karpa, Volodymyr I; Markowitz, Joseph; Bingman, Anissa K; Geyer, Susan M; Kendra, Kari L; Carson, William E

Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial

卡博替尼:晚期肾细胞癌骨转移患者的新标准治疗方案?METEOR试验的亚组分析

Escudier, Bernard; Powles, Thomas; Motzer, Robert J; Olencki, Thomas; Arén Frontera, Osvaldo; Oudard, Stephane; Rolland, Frederic; Tomczak, Piotr; Castellano, Daniel; Appleman, Leonard J; Drabkin, Harry; Vaena, Daniel; Milwee, Steven; Youkstetter, Jillian; Lougheed, Julie C; Bracarda, Sergio; Choueiri, Toni K

Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology

默克尔细胞癌,2018 年 1.2018 版,NCCN 肿瘤临床实践指南

Bichakjian, Christopher K; Olencki, Thomas; Aasi, Sumaira Z; Alam, Murad; Andersen, James S; Blitzblau, Rachel; Bowen, Glen M; Contreras, Carlo M; Daniels, Gregory A; Decker, Roy; Farma, Jeffrey M; Fisher, Kris; Gastman, Brian; Ghosh, Karthik; Grekin, Roy C; Grossman, Kenneth; Ho, Alan L; Lewis, Karl D; Loss, Manisha; Lydiatt, Daniel D; Messina, Jane; Nehal, Kishwer S; Nghiem, Paul; Puzanov, Igor; Schmults, Chrysalyne D; Shaha, Ashok R; Thomas, Valencia; Xu, Yaohui G; Zic, John A; Hoffmann, Karin G; Engh, Anita M

Nitric Oxide Production by Myeloid-Derived Suppressor Cells Plays a Role in Impairing Fc Receptor-Mediated Natural Killer Cell Function

髓系抑制细胞产生的一氧化氮在损害 Fc 受体介导的自然杀伤细胞功能中发挥作用

Andrew Stiff #, Prashant Trikha #, Bethany Mundy-Bosse, Elizabeth McMichael, Thomas A Mace, Brooke Benner, Kari Kendra, Amanda Campbell, Shalini Gautam, David Abood, Ian Landi, Vincent Hsu, Megan Duggan, Robert Wesolowski, Matthew Old, John Harrison Howard, Lianbo Yu, Nancy Stasik, Thomas Olencki, N

Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update

卡博替尼对比舒尼替尼作为中危或高危转移性肾细胞癌一线治疗(A031203 CABOSUN 随机试验):独立审查的无进展生存期和总生存期更新

Choueiri, Toni K; Hessel, Colin; Halabi, Susan; Sanford, Ben; Michaelson, M Dror; Hahn, Olwen; Walsh, Meghara; Olencki, Thomas; Picus, Joel; Small, Eric J; Dakhil, Shaker; Feldman, Darren R; Mangeshkar, Milan; Scheffold, Christian; George, Daniel; Morris, Michael J

Corrigendum to 'Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update' [Eur J Cancer 94 (May 2018) 115-125]

对“卡博替尼与舒尼替尼作为中危或高危转移性肾细胞癌初始治疗(A031203 CABOSUN 随机试验):独立审查的无进展生存期和总生存期更新”的更正[Eur J Cancer 94(2018 年 5 月)115-125]

Choueiri, Toni K; Hessel, Colin; Halabi, Susan; Sanford, Ben; Michaelson, M Dror; Hahn, Olwen; Walsh, Meghara; Olencki, Thomas; Picus, Joel; Small, Eric J; Dakhil, Shaker; Feldman, Darren R; Mangeshkar, Milan; Scheffold, Christian; George, Daniel; Morris, Michael J